Medwave seeks US OK for new BP technology:
This article was originally published in Clinica
Medwave has submitted to the US FDA a 510(k) marketing application for its noninvasive blood pressure monitoring system, Primo. The product, which can obtain a blood pressure reading in around 15 seconds, produces readings comparable to an invasive catheter. It features an "intuitive" design that promotes ease of use applications, claimed the Danvers, Massachusetts firm, adding that the monitor provided cost benefits for caregivers in that there is no need for calibration for the life of the product. Medwave believes that Primo could address markets worth around $600m in annual revenue.